Dishman Carbogen Amcis Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Dishman Carbogen AmcisDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -60.7% zurückgegangen, während in der Branche Life Sciences die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 6.2% pro Jahr.

Wichtige Informationen

-60.7%

Wachstumsrate der Gewinne

-60.5%

EPS-Wachstumsrate

Life Sciences Wachstum der Industrie11.2%
Wachstumsrate der Einnahmen6.2%
Eigenkapitalrendite-3.0%
Netto-Marge-6.6%
Letzte Ertragsaktualisierung30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

The Market Doesn't Like What It Sees From Dishman Carbogen Amcis Limited's (NSE:DCAL) Revenues Yet

Oct 15
The Market Doesn't Like What It Sees From Dishman Carbogen Amcis Limited's (NSE:DCAL) Revenues Yet

Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 31% Share Price Plunge

Jun 01
Why Investors Shouldn't Be Surprised By Dishman Carbogen Amcis Limited's (NSE:DCAL) 31% Share Price Plunge

Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Feb 25
Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Dec 29
Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?

Jun 22
Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?

Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?

Feb 14
Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?

Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky

Jun 22
Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky

Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings

May 18
Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings

Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet

Mar 14
Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet

We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt

Aug 23
We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt

Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching

Apr 29
Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching

Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet

Mar 16
Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet

A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns

Feb 23
A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns

How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?

Feb 05
How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?

Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?

Jan 23
Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?

What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Jan 10
What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?

Dec 23
Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?

Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Dec 05
Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt

Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Nov 17
Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate

If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%

Oct 23
If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%

What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Sep 27
What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation

Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?

Sep 06
Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?

Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk

Aug 03
Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk

Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings

Jul 20
Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings

Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings

Jul 06
Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings

Aufschlüsselung der Einnahmen und Ausgaben

Wie Dishman Carbogen Amcis Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

NSEI:DCAL Einnahmen, Ausgaben und Erträge (INR Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Sep 2426,186-1,74012,7450
30 Jun 2424,162-2,48012,2990
31 Mar 2426,158-1,53412,1610
31 Dec 2325,796-1,54211,5100
30 Sep 2325,683-47711,1470
30 Jun 2325,957-16810,7520
31 Mar 2324,129-29810,3820
31 Dec 2223,634-3710,4520
30 Sep 2222,856-15210,3000
30 Jun 2221,306609,9880
31 Mar 2221,4071809,8890
31 Dec 2121,013-7249,5800
30 Sep 2120,078-1,2399,2730
30 Jun 2119,884-1,2779,0720
31 Mar 2119,120-1,6518,8220
31 Dec 2018,9464198,6400
30 Sep 2019,6839088,3220
30 Jun 2019,9611,2467,9240
31 Mar 2020,4361,5857,7200
31 Dec 1921,8121,8378,2280
30 Sep 1921,1792,0228,0860
30 Jun 1920,9832,0507,3610
31 Mar 1920,5862,1037,7180
31 Dec 1818,9241,8627,3310
30 Sep 1818,7451,7687,1320
30 Jun 1818,8261,8126,5410
31 Mar 1816,9481,5466,7660
31 Dec 1717,8541,5376,8440
30 Sep 1716,8401,3836,5680
30 Jun 1716,7781,2825,9440
31 Mar 1717,1941,4546,4960
31 Dec 1612,0389534,240-35
31 Mar 16689510
31 Mar 150-500

Qualität der Erträge: DCAL ist derzeit unrentabel.

Wachsende Gewinnspanne: DCAL ist derzeit unrentabel.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: DCAL ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 60.7% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von DCAL verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: DCAL ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Life Sciences (37.9%) erschwert.


Eigenkapitalrendite

Hohe Eigenkapitalrendite: DCAL hat eine negative Eigenkapitalrendite (-3.03%), da es derzeit unrentabel ist.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren